Cantor Fitzgerald Forecasts Codexis FY2025 Earnings

Codexis, Inc. (NASDAQ:CDXS) – Cantor Fitzgerald issued their FY2025 earnings per share estimates for Codexis in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the biotechnology company will post earnings of ($0.51) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $11.00 price objective on the stock. The consensus estimate for Codexis’ current full-year earnings is ($0.77) per share.

Codexis (NASDAQ:CDXS) last announced its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.04). Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. The firm had revenue of $12.83 million during the quarter, compared to analysts’ expectations of $11.64 million. During the same period last year, the company earned ($0.26) earnings per share.

Separately, Benchmark reiterated a “hold” rating on shares of Codexis in a research note on Monday, November 4th.

Codexis Price Performance

CDXS stock opened at $4.87 on Thursday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.15 and a current ratio of 3.21. Codexis has a 1-year low of $2.53 and a 1-year high of $6.08. The business has a 50 day simple moving average of $4.86 and a two-hundred day simple moving average of $3.78.

Hedge Funds Weigh In On Codexis

Several institutional investors and hedge funds have recently modified their holdings of CDXS. Tallon Kerry Patrick acquired a new position in Codexis in the fourth quarter valued at approximately $2,018,000. abrdn plc boosted its holdings in Codexis by 62.5% during the third quarter. abrdn plc now owns 800,410 shares of the biotechnology company’s stock worth $2,465,000 after buying an additional 307,762 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Codexis by 23.4% during the third quarter. Assenagon Asset Management S.A. now owns 1,103,442 shares of the biotechnology company’s stock valued at $3,399,000 after buying an additional 209,207 shares during the period. AQR Capital Management LLC raised its position in shares of Codexis by 82.4% in the second quarter. AQR Capital Management LLC now owns 237,272 shares of the biotechnology company’s stock worth $736,000 after acquiring an additional 107,205 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of Codexis by 34.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 340,762 shares of the biotechnology company’s stock valued at $1,056,000 after acquiring an additional 87,457 shares during the period. Institutional investors and hedge funds own 78.54% of the company’s stock.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.